Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoKnife® System Clinical Experience Featured at Society of Surgical Oncology Conference

Abstract:
AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced presentations on NanoKnife® System clinical experience were given at the Society of Surgical Oncology (SSO) 2012 conference that took place March 21-24, 2012, in Orlando, Fla.

NanoKnife® System Clinical Experience Featured at Society of Surgical Oncology Conference

Albany, NY | Posted on April 2nd, 2012

An oral presentation titled, "Image Guided Irreversible Electroporation in Locally Advanced Pancreatic Cancer: Improved Overall Survival," was presented by Dr. Robert Martin, University Of Louisville, Department of Surgery, Division of Surgical Oncology, Louisville, Ky. Additional authors included Doctors David Hays and Whitney Goodwin, Baptist Health, Little Rock, Ark.; and Doctors Kellie McFarlin, Madhu Prasad and Vic Valanovich, Henry Ford Hospital, Detroit, Mich.

In connection with a registry administered by the University of Louisville, Department of Surgery, Division of Surgical Oncology, 44 patients underwent procedures with the NanoKnife System for unresectable pancreatic cancer from December 2009 to October 2010. Overall survival was evaluated and compared to 85 matched stage three patients treated with standard therapy defined as chemotherapy and radiation therapy alone.

The authors noted that ninety percent of the patients treated with the NanoKnife System had chemotherapy alone, or chemo-radiation therapy, for a median duration of five months before a procedure with the NanoKnife System. Seventy-three percent underwent chemotherapy or chemo-radiation after a procedure with the NanoKnife System. The 90-day mortality in patients who had procedures with the NanoKnife System was two percent. Comparing patients with NanoKnife System procedures to those receiving standard therapy, the authors reported a significant improvement in local progression-free survival, 14 versus six months. Improvement also was reported for distant progression-free survival, 15 versus nine months. Overall survival was 20 months versus 13 months.

A poster presentation, titled "The Successful Implementation of Irreversible Electroporation for Tissue Ablation in Primary and Secondary Tumors of the Liver and Pancreas," also was given. The authors are Doctors Gary Deutsch; H. Walden, Mansoor Beg, Charles Conte, James Sullivan and John Wang, North Shore University Hospital, Hofstra-NSLIJ School of Medicine, Manhasset, N.Y.

Abstracts for the presentations may be found via the following link and are listed as abstract 18 and P243 respectively:

www.surgonc.org/uploads/SSO_Annual_Cancer_Symposium_2012_Abstract_Supplement.pdf

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

####

About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011, and AngioDynamics’ Form 10-Q for the quarterly period ended November 30, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics provided grants in support of the studies referred to in this release.

For more information, please click here

Contacts:
AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 x1608

or
Investor Relations Contacts:
EVC Group, Inc.
Greg Gin, 646-445-4801

Doug Sherk, 415-652-9100

or
Media Contact:
EVC Group, Inc.
Chris Gale, 646-201-5431

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Production of Toxic Gas Sensor Based on Nanorods July 28th, 2014

Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara July 28th, 2014

Stanford team achieves 'holy grail' of battery design: A stable lithium anode - Engineers use carbon nanospheres to protect lithium from the reactive and expansive problems that have restricted its use as an anode July 27th, 2014

Nanomedicine

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

New imaging agent provides better picture of the gut July 25th, 2014

Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

Announcements

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Production of Toxic Gas Sensor Based on Nanorods July 28th, 2014

Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara July 28th, 2014

Stanford team achieves 'holy grail' of battery design: A stable lithium anode - Engineers use carbon nanospheres to protect lithium from the reactive and expansive problems that have restricted its use as an anode July 27th, 2014

Events/Classes

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

NNCO Announces an Interactive Webinar: Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy July 23rd, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE